GlobalData on MSN5d
Regeneron’s Dupixent approved as first adolescent CRSwNP treatmentThe FDA has expanded the approval of Dupixent to include adolescents aged 12 to 17 years with inadequately controlled CRSwNP.
CRSwNP is a chronic disease of the upper airway, driven in part by type 2 inflammation, that obstructs the sinuses and nasal passages. It can lead to breathing difficulties, nasal congestion and ...
The Food and Drug Administration (FDA) has expanded the approval of Dupixent ® (dupilumab) to include add-on maintenance treatment of adolescent patients aged 12 to 17 years with inadequately ...
This decision follows the initial approval for patients aged 18 and older in June 2019. CRSwNP is a chronic inflammatory condition of the sinuses and nasal passages that can significantly impact ...
Following Priority Review, Dupixent is now available to patients as young as 12 years with inadequately controlled CRSwNPCurrent treatment ...
TARRYTOWN, N.Y. - The U.S. Food and Drug Administration (FDA) has expanded the approval for Dupixent® (dupilumab) to include adolescent patients aged 12 to 17 with inadequately controlled chronic ...
This approval expands the initial June 2019 FDA approval in CRSwNP for patients aged 18 years and older. The FDA evaluated Dupixent for this expanded indication under Priority Review, which is ...
This approval expands the initial June 2019 FDA approval in CRSwNP for patients aged 18 years and older. The FDA evaluated Dupixent for this expanded indication under Priority Review, which is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback